The evaluation of tumor-infiltrated CD4+CD25+Foxp3+ regulatory T cells designated that treatment of mice with TEXomiR significantly (P = 0.032) decreases the tumor-infiltrated CD4+CD25+Foxp3+ T cells in the TEXomiR group compared with the PBS group (Figures 9A,B). Here, FOXP3 is linked to neoplasm.